Kolltan Pharma Raises $10 Million
Kolltan Pharmaceuticals Inc., a New Haven, Conn.-based oncology therapeutics startup, has raised $8.5 million in Series B funding from Celtic Therapeutics Holdings and and Tichenor Ventures. Kolltan also received another $1.5 million that can be applied either to a product development option with Celtic Therapeutics affiliate or converted into Series B stock. The company previously raised around $40 million in Series A funding from firms like Purdue Pharma, HBM BioVentures and Elm Street Ventures.
20 January 2010•3 mins read
